Q-omics provides the consensus-scored MRPS15 profile across patient tissues and cancer cell-line models. MRPS15 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MRPS15 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, MRPS15 protein abundance shows 28,086 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where MRPS15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS15 survival associations across molecular data types. MRPS15 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS15 RNA expression–survival associations across cancer types. High MRPS15 expression shows unfavorable associations in KIRC, KICH, ACC, LIHC, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MRPS15 RNA expression.
This table summarizes MRPS15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPS15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS15 shows higher tumor expression in BLCA, HNSC, LIHC, LUAD, COAD and UCEC. The BLCA box plot shows higher MRPS15 RNA expression in tumor versus normal tissue (log2 FC = +0.921, t-test p < 0.001).
This table shows molecular features associated with MRPS15 in patient tissues and cancer cell lines. In patient samples, MRPS15 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPS15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
